Prestige Consmr Healthcare Inc Financials
Prestige Consmr Healthcare Inc (PBH) reported $1.1B in revenue for fiscal year 2026, down 4.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
PBH's stable margin engine and very low reinvestment needs turn flat sales into debt reduction, buybacks, and durable cash flow.
The striking feature is that FY2023's accounting loss did not interrupt the cash engine: net income fell to-$82.3M while operating cash flow still reached$229.7M . Because revenue and gross margin barely moved before profitability snapped back in FY2024, the weak year looks more like a below-gross-profit disruption than a lasting change in core product economics.
Free cash flow stays close to operating cash flow because capital spending is tiny, only
Leverage has eased materially: long-term debt fell from
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Prestige Consmr Healthcare Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Prestige Consmr Healthcare Inc has an operating margin of 28.4%, meaning the company retains $28 of operating profit per $100 of revenue. This strong profitability earns a score of 82/100, reflecting efficient cost management and pricing power. This is down from 29.6% the prior year.
Prestige Consmr Healthcare Inc's revenue declined 4.3% year-over-year, from $1.1B to $1.1B. This contraction results in a growth score of 27/100.
Prestige Consmr Healthcare Inc has elevated debt relative to equity (D/E of 0.53), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 23/100, reflecting increased financial risk.
With a current ratio of 3.57, Prestige Consmr Healthcare Inc holds $3.57 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 83/100.
Prestige Consmr Healthcare Inc converts 22.6% of revenue into free cash flow ($246.4M). This strong cash generation earns a score of 89/100.
Prestige Consmr Healthcare Inc's ROE of 10.1% shows moderate profitability relative to equity, earning a score of 63/100. This is down from 11.7% the prior year.
Prestige Consmr Healthcare Inc scores 2.32, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Prestige Consmr Healthcare Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Prestige Consmr Healthcare Inc generates $1.35 in operating cash flow ($257.6M OCF vs $190.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Prestige Consmr Healthcare Inc earns $7.31 in operating income for every $1 of interest expense ($309.4M vs $42.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Prestige Consmr Healthcare Inc generated $1.1B in revenue in fiscal year 2026. This represents a decrease of 4.3% from the prior year.
Prestige Consmr Healthcare Inc's EBITDA was $340.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.2% from the prior year.
Prestige Consmr Healthcare Inc reported $190.3M in net income in fiscal year 2026. This represents a decrease of 11.3% from the prior year.
Prestige Consmr Healthcare Inc earned $3.91 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 8.9% from the prior year.
Cash & Balance Sheet
Prestige Consmr Healthcare Inc generated $246.4M in free cash flow in fiscal year 2026, representing cash available after capex. This represents an increase of 1.3% from the prior year.
Prestige Consmr Healthcare Inc held $63.9M in cash against $994.0M in long-term debt as of fiscal year 2026.
Not reported for fiscal year 2026.
Margins & Returns
Prestige Consmr Healthcare Inc's gross margin was 54.7% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is down 1.0 percentage points from the prior year.
Prestige Consmr Healthcare Inc's operating margin was 28.4% in fiscal year 2026, reflecting core business profitability. This is down 1.2 percentage points from the prior year.
Prestige Consmr Healthcare Inc's net profit margin was 17.5% in fiscal year 2026, showing the share of revenue converted to profit. This is down 1.4 percentage points from the prior year.
Prestige Consmr Healthcare Inc's ROE was 10.1% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 1.6 percentage points from the prior year.
Capital Allocation
Prestige Consmr Healthcare Inc spent $156.3M on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 203.4% from the prior year.
Prestige Consmr Healthcare Inc invested $11.2M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 35.9% from the prior year.
Not reported for fiscal year 2026.
PBH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B-4.3% | $1.1B+1.1% | $1.1B-0.2% | $1.1B+3.8% | $1.1B+15.2% | $943.4M-2.0% | $963.0M-1.3% | $975.8M-6.3% | $1.0B+18.0% | $882.1M+9.4% | $806.2M+13.0% | $713.5M+19.8% | $595.6M-3.4% | $616.9M+39.9% | $441.1M |
| Cost of Revenue | $513.5M | $493.1M-2.0% | $503.3M+0.5% | $500.9M-0.3% | $502.4M+7.8% | $466.2M+17.8% | $395.9M-3.6% | $410.8M-2.2% | $420.2M-9.6% | $464.7M+21.7% | $381.8M+12.6% | $339.0M | N/A | N/A | N/A | N/A |
| Gross Profit | $591.4M | $595.6M-6.1% | $634.5M+1.6% | $624.4M-0.1% | $625.3M+0.7% | $620.6M+13.4% | $547.5M-0.9% | $552.2M-0.6% | $555.6M-3.6% | $576.5M+15.2% | $500.3M+7.1% | $467.2M+15.0% | $406.2M+21.1% | $335.6M-2.4% | $343.7M+51.2% | $227.4M |
| SG&A Expenses | $131.3M | $116.4M+7.6% | $108.2M+1.9% | $106.2M-1.1% | $107.4M-0.1% | $107.5M+29.3% | $83.1M-6.7% | $89.1M-0.7% | $89.8M+5.1% | $85.4M-4.2% | $89.1M+23.1% | $72.4M-10.9% | $81.3M+67.6% | $48.5M-5.8% | $51.5M-9.2% | $56.7M |
| Operating Income | $290.2M | $309.4M-8.1% | $336.8M-1.7% | $342.4M+1627.7% | -$22.4M-106.8% | $329.9M+10.9% | $297.4M+2.1% | $291.2M+331.3% | $67.5M-68.7% | $215.5M+4.8% | $205.6M-21.0% | $260.3M+25.4% | $207.6M+10.0% | $188.6M-1.7% | $191.9M+86.6% | $102.8M |
| Interest Expense | N/A | -$42.3M-2452.2% | $1.8M-65.4% | $5.2M+18.2% | $4.4M-93.2% | $64.3M-21.9% | $82.3M-14.4% | $96.2M-8.4% | $105.1M-1.1% | $106.3M+13.6% | $93.5M+9.6% | $85.3M+4.9% | $81.3M+18.5% | $68.6M-18.7% | $84.4M+104.2% | $41.3M |
| Income Tax | $62.2M | $67.2M-3.4% | $69.6M+4.3% | $66.7M+674.4% | -$11.6M-120.3% | $57.1M+44.8% | $39.4M-19.3% | $48.9M+2267.2% | -$2.3M+99.0% | -$232.5M-660.8% | $41.5M-27.6% | $57.3M+16.4% | $49.2M+68.9% | $29.1M-28.1% | $40.5M+69.3% | $23.9M |
| Net Income | $172.0M | $190.3M-11.3% | $214.6M+2.5% | $209.3M+354.3% | -$82.3M-140.1% | $205.4M+24.7% | $164.7M+15.7% | $142.3M+497.4% | -$35.8M-110.5% | $339.6M+389.3% | $69.4M-30.5% | $99.9M+27.7% | $78.3M+7.8% | $72.6M+10.9% | $65.5M+76.0% | $37.2M |
| EPS (Diluted) | — | $3.91-8.9% | $4.29+2.9% | $4.17+352.7% | -$1.65-140.8% | $4.04+24.3% | $3.25+16.9% | $2.78+502.9% | -$0.69-110.9% | $6.34+387.7% | $1.30-30.9% | $1.88+26.2% | $1.49+7.2% | $1.39+9.4% | $1.27+74.0% | $0.73 |
Not reported in any period shown, so not listed: R&D Expenses.
TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PBH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.5B+2.7% | $3.4B+2.5% | $3.3B-1.1% | $3.4B-8.6% | $3.7B+7.0% | $3.4B-2.4% | $3.5B+2.1% | $3.4B-8.5% | $3.8B-3.9% | $3.9B+32.6% | $2.9B+11.6% | $2.6B+47.1% | $1.8B+3.2% | $1.7B-1.1% | $1.8B |
| Current Assets | $431.5M-3.8% | $448.3M+19.5% | $375.0M-4.3% | $391.7M+33.6% | $293.3M+8.7% | $269.8M-26.2% | $365.7M+21.5% | $300.9M-0.8% | $303.5M-9.3% | $334.4M+34.3% | $249.0M+23.5% | $201.7M+13.8% | $177.2M+7.9% | $164.2M+11.7% | $147.0M |
| Cash & Equivalents | $63.9M-34.8% | $97.9M+110.6% | $46.5M-20.6% | $58.5M+115.2% | $27.2M-15.8% | $32.3M-65.9% | $94.8M+244.2% | $27.5M-15.4% | $32.5M-22.2% | $41.9M+53.7% | $27.2M+27.7% | $21.3M-24.8% | $28.3M+80.8% | $15.7M-17.6% | $19.0M |
| Inventory | $159.1M+7.7% | $147.7M+6.5% | $138.7M-14.4% | $162.1M+34.7% | $120.3M+4.7% | $115.0M-0.9% | $116.0M-3.2% | $119.9M+1.1% | $118.5M+2.5% | $115.6M+26.7% | $91.3M+23.3% | $74.0M+12.8% | $65.6M+8.9% | $60.2M+17.8% | $51.1M |
| Accounts Receivable | $191.9M-1.2% | $194.3M+9.9% | $176.8M+5.8% | $167.0M+19.9% | $139.3M+21.5% | $114.7M-23.8% | $150.5M+1.2% | $148.8M+5.6% | $140.9M+3.0% | $136.7M+43.6% | $95.2M+8.4% | $87.9M+35.1% | $65.0M-11.0% | $73.1M0.0% | $73.1M |
| Goodwill | $581.1M+10.2% | $527.4M-0.1% | $527.7M0.0% | $527.6M-8.9% | $579.0M+0.2% | $578.1M+0.5% | $575.2M-0.6% | $578.6M-6.7% | $620.1M+0.8% | $615.3M+70.8% | $360.2M+23.9% | $290.7M+52.2% | $190.9M+13.9% | $167.5M-3.5% | $173.7M |
| Total Liabilities | $1.6B+2.5% | $1.6B-5.8% | $1.7B-12.8% | $1.9B-8.9% | $2.1B+1.1% | $2.1B-11.6% | $2.3B-0.1% | $2.3B-9.2% | $2.6B-16.4% | $3.1B+40.1% | $2.2B+9.4% | $2.0B+63.5% | $1.2B-2.3% | $1.3B-6.9% | $1.4B |
| Current Liabilities | $120.9M+13.4% | $106.6M-8.9% | $117.0M-27.2% | $160.7M+12.1% | $143.4M+17.4% | $122.1M-18.5% | $149.9M+18.0% | $127.0M+3.1% | $123.2M-24.0% | $162.0M+51.9% | $106.7M+7.7% | $99.0M+17.4% | $84.4M-12.7% | $96.7M+51.2% | $63.9M |
| Long-Term Debt | $994.0M+0.2% | $992.4M-12.6% | $1.1B-15.7% | $1.3B-8.9% | $1.5B-0.2% | $1.5B-14.5% | $1.7B-3.8% | $1.8B-9.8% | $2.0B-9.2% | $2.2B+35.0% | $1.6B+4.1% | $1.6B+67.1% | $934.4M-3.8% | $970.9M-13.6% | $1.1B |
| Total Equity | $1.9B+2.9% | $1.8B+10.9% | $1.7B+14.4% | $1.4B-8.3% | $1.6B+16.1% | $1.4B+16.0% | $1.2B+6.9% | $1.1B-7.0% | $1.2B+43.3% | $822.5M+10.5% | $744.3M+18.6% | $627.6M+11.4% | $563.4M+17.9% | $477.9M+18.7% | $402.7M |
| Retained Earnings | $1.7B+12.2% | $1.6B+16.0% | $1.3B+18.5% | $1.1B-6.8% | $1.2B+20.4% | $1.0B+19.5% | $844.1M+20.3% | $701.8M-4.7% | $736.3M+85.6% | $396.7M+21.2% | $327.3M+43.9% | $227.4M+52.5% | $149.1M+95.6% | $76.2M+609.8% | $10.7M |
PBH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $249.4M | $257.6M+2.4% | $251.5M+1.0% | $248.9M+8.4% | $229.7M-11.6% | $259.9M+10.3% | $235.6M+8.5% | $217.1M+14.7% | $189.3M-9.9% | $210.1M+41.3% | $148.7M-15.7% | $176.3M+12.8% | $156.3M+40.0% | $111.6M-18.9% | $137.6M+104.0% | $67.5M |
| Capital Expenditures | $14.0M | $11.2M+35.9% | $8.2M-13.9% | $9.6M+22.7% | $7.8M-19.3% | $9.6M-56.7% | $22.2M+52.8% | $14.6M+38.9% | $10.5M-16.4% | $12.5M+321.0% | $3.0M-16.6% | $3.6M-41.5% | $6.1M+120.7% | $2.8M-73.1% | $10.3M+1594.4% | $606K |
| Free Cash Flow | $235.4M | $246.4M+1.3% | $243.3M+1.6% | $239.4M+7.9% | $221.9M-11.3% | $250.3M+17.3% | $213.4M+5.3% | $202.6M+13.3% | $178.8M-9.5% | $197.6M+35.6% | $145.7M-15.7% | $172.7M+15.0% | $150.2M+38.0% | $108.8M-14.5% | $127.3M+90.5% | $66.8M |
| Investing Cash Flow | -$1.2B | -$136.8M-684.1% | -$17.5M+13.2% | -$20.1M-73.6% | -$11.6M+95.5% | -$256.5M-1053.2% | -$22.2M-34.2% | -$16.6M-129.9% | $55.4M+579.4% | -$11.6M+98.3% | -$694.6M-211.5% | -$223.0M+72.3% | -$805.3M-1289.0% | -$58.0M-616.7% | $11.2M+101.7% | -$662.2M |
| Financing Cash Flow | $898.7M | -$156.1M+14.3% | -$182.1M+24.5% | -$241.0M-29.7% | -$185.8M-2355.4% | -$7.6M+97.3% | -$279.4M-112.6% | -$131.4M+47.3% | -$249.3M-19.3% | -$209.0M-137.2% | $561.0M+977.2% | $52.1M-91.9% | $643.3M+1663.1% | -$41.2M+72.9% | -$152.1M-125.3% | $600.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | N/A |
| Share Buybacks | $121.5M | $156.3M+203.4% | $51.5M+106.0% | $25.0M-50.0% | $50.0M | $0-100.0% | $11.9M-79.1% | $56.7M+13.5% | $50.0M | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PBH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.7%-1.0pp | 55.8%+0.3pp | 55.5%0.0pp | 55.5%-1.7pp | 57.1%-0.9pp | 58.0%+0.7pp | 57.3%+0.4pp | 56.9%+1.6pp | 55.4%-1.4pp | 56.7%-1.2pp | 58.0%+1.0pp | 56.9%+0.6pp | 56.3%+0.6pp | 55.7%+4.2pp | 51.5% |
| Operating Margin | 28.4%-1.2pp | 29.6%-0.8pp | 30.4%+32.4pp | -2.0%-32.4pp | 30.4%-1.2pp | 31.5%+1.3pp | 30.2%+23.3pp | 6.9%-13.8pp | 20.7%-2.6pp | 23.3%-9.0pp | 32.3%+3.2pp | 29.1%-2.6pp | 31.7%+0.6pp | 31.1%+7.8pp | 23.3% |
| Net Margin | 17.5%-1.4pp | 18.9%+0.3pp | 18.6%+25.9pp | -7.3%-26.2pp | 18.9%+1.4pp | 17.5%+2.7pp | 14.8%+18.4pp | -3.7%-36.3pp | 32.6%+24.7pp | 7.9%-4.5pp | 12.4%+1.4pp | 11.0%-1.2pp | 12.2%+1.6pp | 10.6%+2.2pp | 8.4% |
| Return on Equity | 10.1%-1.6pp | 11.7%-0.9pp | 12.7%+18.3pp | -5.7%-18.7pp | 13.0%+0.9pp | 12.1%0.0pp | 12.2%+15.4pp | -3.3%-32.1pp | 28.8%+20.4pp | 8.4%-5.0pp | 13.4%+1.0pp | 12.5%-0.4pp | 12.9%-0.8pp | 13.7%+4.5pp | 9.2% |
| Return on Assets | 5.5%-0.9pp | 6.3%0.0pp | 6.3%+8.8pp | -2.5%-8.1pp | 5.6%+0.8pp | 4.8%+0.8pp | 4.0%+5.1pp | -1.0%-10.1pp | 9.0%+7.3pp | 1.8%-1.6pp | 3.4%+0.4pp | 3.0%-1.1pp | 4.0%+0.3pp | 3.8%+1.6pp | 2.1% |
| Current Ratio | 3.57-0.6x | 4.20+1.0x | 3.20+0.8x | 2.44+0.4x | 2.04-0.2x | 2.21-0.2x | 2.44+0.1x | 2.37-0.1x | 2.46+0.4x | 2.06-0.3x | 2.33+0.3x | 2.04-0.1x | 2.10+0.4x | 1.70-0.6x | 2.30 |
| Debt-to-Equity | 0.530.0x | 0.54-0.1x | 0.69-0.2x | 0.930.0x | 0.94-0.2x | 1.09-0.4x | 1.48-0.2x | 1.640.0x | 1.69-1.0x | 2.67+0.5x | 2.18-0.3x | 2.49+0.8x | 1.66-0.4x | 2.03-0.8x | 2.79 |
| FCF Margin | 22.6%+1.3pp | 21.4%+0.1pp | 21.3%+1.6pp | 19.7%-3.4pp | 23.0%+0.4pp | 22.6%+1.6pp | 21.0%+2.7pp | 18.3%-0.7pp | 19.0%+2.5pp | 16.5%-4.9pp | 21.4%+0.4pp | 21.1%+2.8pp | 18.3%-2.4pp | 20.6%+5.5pp | 15.2% |
Similar Companies
Where Prestige Consmr Healthcare Inc Ranks
Frequently Asked Questions
What is Prestige Consmr Healthcare Inc's annual revenue?
Prestige Consmr Healthcare Inc (PBH) reported $1.1B in total revenue for fiscal year 2026. This represents a -4.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Prestige Consmr Healthcare Inc's revenue growing?
Prestige Consmr Healthcare Inc (PBH) revenue declined by 4.3% year-over-year, from $1.1B to $1.1B in fiscal year 2026.
Is Prestige Consmr Healthcare Inc profitable?
Yes, Prestige Consmr Healthcare Inc (PBH) reported a net income of $190.3M in fiscal year 2026, with a net profit margin of 17.5%.
What is Prestige Consmr Healthcare Inc's EBITDA?
Prestige Consmr Healthcare Inc (PBH) had EBITDA of $340.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Prestige Consmr Healthcare Inc have?
As of fiscal year 2026, Prestige Consmr Healthcare Inc (PBH) had $63.9M in cash and equivalents against $994.0M in long-term debt.
What is Prestige Consmr Healthcare Inc's gross margin?
Prestige Consmr Healthcare Inc (PBH) had a gross margin of 54.7% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Prestige Consmr Healthcare Inc's operating margin?
Prestige Consmr Healthcare Inc (PBH) had an operating margin of 28.4% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Prestige Consmr Healthcare Inc's net profit margin?
Prestige Consmr Healthcare Inc (PBH) had a net profit margin of 17.5% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Prestige Consmr Healthcare Inc's return on equity (ROE)?
Prestige Consmr Healthcare Inc (PBH) has a return on equity of 10.1% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Prestige Consmr Healthcare Inc's free cash flow?
Prestige Consmr Healthcare Inc (PBH) generated $246.4M in free cash flow during fiscal year 2026. This represents a 1.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Prestige Consmr Healthcare Inc's operating cash flow?
Prestige Consmr Healthcare Inc (PBH) generated $257.6M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Prestige Consmr Healthcare Inc's total assets?
Prestige Consmr Healthcare Inc (PBH) had $3.5B in total assets as of fiscal year 2026, including both current and long-term assets.
What are Prestige Consmr Healthcare Inc's capital expenditures?
Prestige Consmr Healthcare Inc (PBH) invested $11.2M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is Prestige Consmr Healthcare Inc's current ratio?
Prestige Consmr Healthcare Inc (PBH) had a current ratio of 3.57 as of fiscal year 2026, which is generally considered healthy.
What is Prestige Consmr Healthcare Inc's debt-to-equity ratio?
Prestige Consmr Healthcare Inc (PBH) had a debt-to-equity ratio of 0.53 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Prestige Consmr Healthcare Inc's return on assets (ROA)?
Prestige Consmr Healthcare Inc (PBH) had a return on assets of 5.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Prestige Consmr Healthcare Inc's Altman Z-Score?
Prestige Consmr Healthcare Inc (PBH) has an Altman Z-Score of 2.32, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Prestige Consmr Healthcare Inc's Piotroski F-Score?
Prestige Consmr Healthcare Inc (PBH) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Prestige Consmr Healthcare Inc's earnings high quality?
Prestige Consmr Healthcare Inc (PBH) has an earnings quality ratio of 1.35x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Prestige Consmr Healthcare Inc cover its interest payments?
Prestige Consmr Healthcare Inc (PBH) has an interest coverage ratio of 7.31x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Prestige Consmr Healthcare Inc?
Prestige Consmr Healthcare Inc (PBH) scores 61 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.